

ASX:NRT
NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

483 M

Board of Directors

Mr John O'Connor
Chairman
Non-Executive Director

Mr Bryce Carmine
Deputy Chairman
Non-Executive Director

Dr James Garner
Chief Executive Officer
Managing Director

Mr Ian Phillips MNZM
Non-Executive Director

Mr Iain Ross
Non-Executive Director

Mr Steven Coffey
Non-Executive Director

MARKET RELEASE

18 April 2017

NOVOGEN SHAREHOLDER INFORMATION SESSION RECORDING

Sydney, 18TH April 2017 Australian oncology-focused biotechnology company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to release a recording of the shareholder information briefing session held in Sydney on Wednesday 12th April.

The event consisted of a presentation by CEO, Dr James Garner followed by a Q&A session.

To view the webcast recording, please copy and paste the URL below into your web browser:

<http://webcasting.boardroom.media/broadcast/58c79565596409733ddb670d>

-Ends-

Media and Investor Relations	Investor Relations (US)
Glen Zurcher E: glen.zurcher@irdepartment.com.au T: +61 420 249 299	Robert Kennedy E: robert.kennedy@novogen.com T: +1 212 519 9832 / +1 646 662 3574